The Goldman Sachs Group Has Lowered Expectations for Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) had its price objective lowered by stock analysts at The Goldman Sachs Group from $10.00 to $5.00 in a report issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would indicate a potential upside of 81.16% from […]
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) had its price objective lowered by stock analysts at The Goldman Sachs Group from $10.00 to $5.00 in a report issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would indicate a potential upside of 81.16% from […]
